Equities research analysts expect Immune Design Corp (NASDAQ:IMDZ) to report earnings per share (EPS) of ($0.39) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Immune Design’s earnings. The highest EPS estimate is ($0.32) and the lowest is ($0.46). Immune Design reported earnings of ($0.57) per share during the same quarter last year, which would indicate a positive year over year growth rate of 31.6%. The company is scheduled to report its next earnings results on Tuesday, March 6th.
According to Zacks, analysts expect that Immune Design will report full-year earnings of ($1.89) per share for the current fiscal year, with EPS estimates ranging from ($2.00) to ($1.76). For the next year, analysts anticipate that the firm will post earnings of ($1.40) per share, with EPS estimates ranging from ($1.58) to ($1.24). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Immune Design.
Immune Design (NASDAQ:IMDZ) last announced its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.52) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.63) by $0.11. The firm had revenue of $0.52 million for the quarter, compared to the consensus estimate of $0.62 million. Immune Design had a negative net margin of 619.62% and a negative return on equity of 68.69%.
Shares of Immune Design (NASDAQ:IMDZ) traded up $0.05 during trading hours on Friday, hitting $3.70. 477,139 shares of the company’s stock were exchanged, compared to its average volume of 596,486. Immune Design has a 1-year low of $3.50 and a 1-year high of $13.05. The stock has a market cap of $180.25, a PE ratio of -1.74 and a beta of 2.36.
In other Immune Design news, CEO Carlos V. Paya sold 7,970 shares of the company’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $4.17, for a total transaction of $33,234.90. Following the completion of the transaction, the chief executive officer now directly owns 114,560 shares in the company, valued at $477,715.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Leo Guthart acquired 20,000 shares of Immune Design stock in a transaction on Monday, January 8th. The shares were bought at an average price of $3.90 per share, with a total value of $78,000.00. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 5,300,000 shares of company stock worth $21,795,000 and have sold 13,959 shares worth $58,209. Corporate insiders own 20.70% of the company’s stock.
A number of large investors have recently bought and sold shares of the business. Schwab Charles Investment Management Inc. raised its position in Immune Design by 59.7% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 54,543 shares of the biotechnology company’s stock worth $213,000 after acquiring an additional 20,400 shares during the period. EAM Investors LLC acquired a new position in Immune Design during the third quarter worth $387,000. Victory Capital Management Inc. raised its position in Immune Design by 4.2% during the third quarter. Victory Capital Management Inc. now owns 2,060,234 shares of the biotechnology company’s stock worth $21,324,000 after acquiring an additional 82,670 shares during the period. California State Teachers Retirement System raised its position in Immune Design by 8.3% during the second quarter. California State Teachers Retirement System now owns 30,174 shares of the biotechnology company’s stock worth $294,000 after acquiring an additional 2,300 shares during the period. Finally, Sectoral Asset Management Inc acquired a new position in Immune Design during the second quarter worth $1,641,000. Institutional investors own 29.34% of the company’s stock.
About Immune Design
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.